Articles tagged with Cancer Medication
Single-arm trials can provide valuable opportunities for speeding up cancer drug development and approval, particularly in small populations with high unmet medical need. Regulatory guidance is being developed to define evidence requirements for SATs, and initial approvals based on SATs have similar success rates to RCTs.
A genetic signature related to metabolism has been identified as a predictor of poor patient prognosis in cancer. The discovery could lead to the development of targeted treatments and personalized therapy approaches. Further validation is needed to confirm the link between mitochondrial function and cancer survival.
A survey by Dr Lidija Kandolf-Sekulovic found that over 5000 European melanoma patients are denied access to innovative treatments each year. In Eastern Europe, only 42% of countries have registered the treatment, and only 18% have full reimbursement coverage.
A survey found that over 5,000 metastatic melanoma patients in Europe are denied access to innovative treatments annually. The inequality affects Eastern and South-Eastern European countries more severely, where only 10% of patients have access to the latest treatment recommended by current guidelines.
Researchers discovered that certain proteins associated with Alzheimer's disease are stored in dormant cancer cells as amyloid bodies. Disaggregation of these bodies can reactivate the cancer cells. The study identified ribosomal intergenic noncoding RNA as a target for drug discovery to prevent amyloid body disaggregation.
Researchers discovered a nuclear protein, EYA1, that contributes to neuroblastoma's aggression. The protein migrates to the nucleus in more aggressive forms of the disease, and its structure can be altered by inhibiting an enzyme called PRMT1.
A new study identifies a previously unknown 'off-switch' for cancer based on the protein TMX1, which can slow down tumor growth and promote resistance to cell death mechanisms. This breakthrough offers hope for developing new therapeutic approaches and improving chemotherapy efficiency.
Researchers at the University of Bradford have discovered a way to prevent chemotherapy resistance in lung cancer by blocking a protein called Ran-GTP. Suppressing this protein also causes cancer cells resistant to gefitinib to become re-sensitized, offering new hope for treatment.
Researchers have identified a strategy to selectively sensitize certain cancer cells to radiation therapy using antibody drug conjugates (ADCs), which could improve tumor control and reduce treatment-related side effects in HER2-positive tumors. The study shows promise in sensitizing these cancers to radiation and chemotherapy.
A new study by University of Connecticut researchers reveals that larger particles, approximately 2 microns in size, are most effective for delivering cancer drugs to tumor sites. Smaller particles, however, tend to skip through blood cells and reach the target site less frequently.
Researchers identify two gut bacteria that activate cancer-fighting T cell immune responses, enhancing the effects of cyclophosphamide. These microbial-driven immune responses predicted longer progression-free survival in advanced lung and ovarian cancer patients treated with chemo-immunotherapy.
Researchers at Sylvester Comprehensive Cancer Center have identified two leukemia-targeting drugs that could be used to treat breast and ovarian cancers by inhibiting HDACs. The study's genetically engineered cell line, BPLER, exhibited key traits associated with cancer stem cells and showed long-lasting effects of the inhibitors.
A new study found that working memory dysfunctions and depression are predictors of non-adherence to oral cancer therapies. The research highlights the importance of assessing cognitive functions before initiating treatment to identify patient profiles at risk of non-adherence.
Researchers found that inhibiting glucose-regulated protein 78 (GRP78) restores sensitivity to tamoxifen in resistant breast cancer. Silencing GRP78 toxically stresses breast cancer cells, leading to cell death. Adding tamoxifen to a GRP78 inhibitor offers an effective combination, enhancing the treatment's effectiveness.
Researchers at Sylvester Comprehensive Cancer Center have identified a receptor that slows breast cancer metastasis when targeted. By blocking the receptor for advanced glycation end-products (RAGE), scientists decreased tumor growth, reduced angiogenesis and inflammation, resulting in lower metastatic rates to the lung and liver.
A recent study found that nearly a third of Medicare patients with chronic myeloid leukemia did not start treatment within six months due to high out-of-pocket costs. However, patients who had access to subsidies to cover drug costs started treatment 50 days sooner on average.
Researchers at Dana-Farber Cancer Institute have found that CML stem cells die in response to inhibition of the protein Ezh2, suggesting a potential cure for some patients. Adding Ezh2-targeting agents to standard treatment could dramatically shorten the treatment period and achieve a cure.
Researchers at The Wistar Institute discovered that BET inhibitors can suppress PD-L1 activity, a major therapeutic target in various tumors. This approach may reduce side effects while enhancing the immune response against cancer.
An experimental cancer drug called pevonedistat has shown significant promise in stopping melanoma, possibly other cancers. The drug works by blocking a specific protein that allows malignant cells to replicate rapidly.
A recent study published in the British Journal of Sports Medicine found that engaging in regular physical activity may help mitigate the risks associated with excessive alcohol consumption. The research analyzed data from eight British population cohorts and discovered a positive correlation between moderate to high levels of physical...
Researchers discovered a combination of two inhibitor drugs that can stop CML completely and significantly lower treatment costs. The study, published in Science Translational Medicine, found encouraging response and cure rates for both chronic phase and blast crisis, offering new hope for patients.
Researchers identified dopamine receptor DRD2 as a key molecule in pancreatic cancer. Blocking the receptor inhibited cancer growth, while its blockade also slowed tumor growth in mice.
The DOE's Exascale Computing Project awards $39.8 million to 15 research teams, including Argonne-led initiatives focusing on cosmology, precision medicine, and urban systems. These projects will drive advancements in high-performance computing for scientific discovery, national security, and economic competitiveness.
A research team from UC San Diego and Monash University identified 38 lead compounds that exhibit strong affinity and high selectivity for the M2 mAChR binding site. These compounds target allosteric binding sites, which are built around a more diverse genetic sequence and structure than orthosteric binding sites.
Researchers have identified three distinct subtypes of esophageal cancer based on genetic signatures, paving the way for tailored treatments. The study suggests patients with specific weaknesses in their DNA repair pathways or immune systems may benefit from targeted therapies, including PARP inhibitors and immunotherapy drugs.
A cardioprotective drug, dexrazoxane, has been found to prevent long-term heart damage in children receiving chemotherapy. The use of dexrazoxane can allow anthracyclines to be given more safely and at higher doses without risking damage to the heart.
Researchers at Cardiff University have discovered a new drug treatment that inhibits memories responsible for cocaine cravings, significantly accelerating the end of drug-seeking behavior. The therapy, currently used in cancer trials, targets the brain's limbic system and could potentially speed up clinical development.
Researchers discovered that the experimental drug AMPI-109 works by flipping a molecular switch on PRL-3 enzyme, which initially puts cancer cells to 'sleep' and then leads to their death. This mechanism could sensitize triple-negative breast cancers to immunotherapy, offering new treatment options.
Researchers discovered that functional regulatory components outside of genes contribute to breast cancer development. Epigenetic changes identified as key drivers of the disease.
A new study published in JAMA Oncology found that 86% of National Comprehensive Cancer Network (NCCN) guideline authors had at least one reported financial conflict of interest. The study revealed significant payments to guideline authors, with an average of $10,011 for general payments and $236,066 for industry research payments.
Researchers have developed a new drug delivery system that uses lower doses of chemotherapeutic drugs at more frequent intervals to control tumors. The approach, called metronomic dosage regimen, shows promise in improving treatment outcomes for complex cancers.
A group of researchers calls for an overhaul of the US process for reviewing coverage of 'off-label' cancer drug use. They found inconsistencies in the five reference guides used to determine reimbursement and weak quality evidence supporting some off-label uses.
A mathematical model suggests that alternating between erlotinib and evofosfamide could help prevent drug resistance in non-small cell lung cancer patients. This treatment schedule is more effective than using either drug alone, according to a study published in PLOS Computational Biology.
Researchers found that oxygen inhibits the anticancer activity of T cells in mice, allowing cancer cells to escape immune attack and establish metastatic colonies. Inhibiting oxygen-sensing proteins in T cells improved the efficacy of immunotherapy, suggesting a new approach for treating cancer.
An international team of researchers identified eight additional types of cancer linked to excess weight and obesity, including stomach, liver, gall bladder, pancreas, ovary, meningioma, thyroid cancer, and multiple myeloma. Limiting weight gain may help reduce the risk of these cancers.
Researchers found a mixture of HER2-positive and HER2-negative breast cancer cells in patients' blood samples, which can lead to tumor progression and resistance to treatment. Combining therapies targeting both populations may be effective in eliminating these cells.
Scientists at Johns Hopkins have discovered a drug combination that specifically targets the metabolic pathways of pancreatic cancer cells. By combining an experimental drug with metformin, researchers were able to shrink tumors by at least 50% in animal models, providing new evidence for treating this aggressive form of cancer.
Researchers at the University of Washington extended the lives of middle-aged mice by up to 60% with a brief rapamycin treatment. The study also highlights the need to understand how dose and gender influence side effects, revealing potential benefits for humans, particularly older adults.
Gerontologists call for clinicians to coordinate care among orthopedics, rehabilitation services, and primary care to reevaluate patients' medication use after a fracture. Clinicians should consider reducing or discontinuing psychotropic medications linked to increased risk of falls and fractures, while prioritizing prescribing drugs k...
Researchers have discovered a new group of compounds that could treat pulmonary hypertension by altering vessel stiffness and its downstream control of metabolism. The findings, published in the Journal of Clinical Investigation, highlight the use of these drugs to target the molecular origins of the disease.
The Center for Innovative Drug Discovery at UTSA and UT Health Science Center has received a $4.6 million grant to support small molecule drug discovery in cancer research. The grant will enable the center to design and create novel molecules to treat various types of cancers.
Scientists identified a target that could lead to the development of new drugs targeting small cell lung cancer while sparing healthy cells. The research found that amplifying a gene's effect spurred tumor growth in mice, but blocking it suppressed tumor growth.
Calixarenes can amplify enzyme catalytic capacity, enabling novel therapeutics in cancer treatment. They also serve as drug delivery vehicles, refining pharmacokinetic profiles and releasing drugs selectively to cancer cells.
A longitudinal study published in PLOS Medicine found a strong association between the duration of adulthood overweight and obesity and an increased risk of developing various types of cancer. For every ten-year increase in adulthood overweight duration, the risk of all obesity-related cancers was associated with a 7% increase.
A recent study published in Nature Genetics has identified 45 noncoding genes associated with prostate cancer development and progression. These genes, known as noncoding RNA, play a key role in activating the disease process.
A study led by Case Western Reserve University researchers has identified a gene, S100P, that may help tumors evade trastuzumab, a common breast cancer treatment. By blocking S100P, tumor cells became sensitive to the drug again.
Researchers found that a cancer drug called etoposide can damage the development of mouse ovary tissue, potentially affecting future fertility. The study suggests that women who take etoposide during pregnancy may have reduced fertility in their daughters.
Researchers analyzed tumor biopsies from 53 melanoma patients treated with immune checkpoint inhibitors to predict treatment response. The study found that adaptive immune responses, such as killer T cells, were significantly higher in responders after treatment began.
A new approach using metabolic imaging could help determine a patient's response to targeted therapies much earlier and with greater precision than traditional tumor shrinkage. This method recognizes a drug's ability to stop cancer cells' energy overuse, allowing for more accurate assessments of treatment success.
Researchers have identified key proteins involved in regulating gene expression in blood cells, which could lead to the development of more effective breast cancer treatments. The study's findings may also help explain how existing drugs work inside human cells.
A new approach using patient-derived cell lines has revealed that pancreatic tumors have diverse genetic mutations, making it challenging to target treatments. The study suggests that personalized medicine can be improved by testing drugs against each patient's specific tumor genetics.
Researchers developed a computational approach to identify individualized targets for therapy by analyzing patient-specific data and mapping complex networks of gene and protein interactions. The study provides insights into the mechanisms behind resistance to anti-androgen therapies and offers a tool for prioritizing effective drugs.
A new tool, HiPub, helps researchers visualize connections between genes, proteins, drugs, and diseases in the vast biomedical literature. It extracts relevant information from text and visualizes it in a network, streamlining knowledge discovery.
Scientists have developed a novel combination of an aptamer and siRNAs to target two tumor-dependent genes in prostate cancer cells. This approach shows promise for effective, less toxic gene therapies for various cancers. The strategy uses two 'missiles' to bind to specific proteins, increasing its grip on cancer targets.
Researchers at Johns Hopkins Kimmel Cancer Center have developed a system using transformed human stem cells to speed up screening of existing drugs for rare brain and other cancers. This method enables more confident comparison with human cells, leading to promising treatments like CDK inhibitors for Group 3 medulloblastoma.
Researchers discovered that a specific molecular pathway is responsible for the metabolic changes in exhausted T cells, which are crucial for effective immune response. By targeting this pathway, scientists may develop new cancer therapies to enhance treatment outcomes.
Researchers at Emory Vaccine Center have identified molecular characteristics of T cells that expand after PD-1 inhibition, paving the way for rational design of combination therapies. The study reveals distinct co-stimulatory molecules and receptors on these revived T cells, which could be targets for drugs.
Researchers discovered that cancer tumors starve immune T cells by shrinking their mitochondria, limiting their ability to fight cancer. Boosting mitochondrial function in T cells improves their performance and could enhance the effectiveness of immunotherapy drugs.
Researchers at George Washington University discovered a connection between CD4 T-cell exhaustion and CD8 T-cell exhaustion in chronic toxoplasmosis. Regulating CD4 T-cells with Blimp-1 protein expression can reverse CD8 T-cell dysfunction, leading to improved pathogen control.
A new study published in The Journal of Urology found no association between phosphodiesterase type 5 inhibitors (PDE-5i) and reduced risk of developing prostate cancer. PDE-5i use was also not linked to lower or higher grade cancer types.